Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity …

The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.

Cingulate INC SEC filing: Form 8-K on 01/29/2024 (0001493152-24-004061).

Filing Date 2.1† Agreement and Plan of Merger, dated August 30, 2021, among Cingulate, Inc., Cingulate Therapeutics LLC, and Cingulate Pharma LLC S-1 9/9/2021 Amended and Restated …

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.

Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with …

Jan 7, 2025 · The subjects in the study were given a single 50mg dose of CTx-1301, Cingulate’s highest dosage, to determine if the medication can be taken in fed and fasted states. No …

The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.

Document Details Form POS AM Filing Date 01 Apr 2024 Document Date 01 Apr 2024 Form Description Post-effective amendment to an S-Type filing Filing Group Registration …

Document Details Form D Filing Date 28 Sep 2021 Document Date 28 Sep 2021 Filing Group Other Company Cingulate Inc Issuer